Camillo Porta Selected Research

Kidney Neoplasms (Kidney Cancer)

1/2022	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
12/2020	Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
10/2020	Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
1/2020	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
2/2019	Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells.
2/2019	Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines.
1/2019	Immune-based combination therapy for metastatic kidney cancer.
1/2019	The adjuvant treatment of kidney cancer: a multidisciplinary outlook.
12/2018	The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative review.
6/2016	Hormone signaling pathways as treatment targets in renal cell cancer (Review).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Camillo Porta Research Topics

Disease

152	Renal Cell Carcinoma (Grawitz Tumor) 07/2022 - 05/2004
102	Neoplasms (Cancer) 05/2022 - 02/2003
29	Kidney Neoplasms (Kidney Cancer) 01/2022 - 04/2007
20	Hepatocellular Carcinoma (Hepatoma) 09/2021 - 07/2007
15	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2006
14	Disease Progression 07/2022 - 01/2006
13	Malignant Mesothelioma 01/2022 - 02/2002
9	Carcinoma (Carcinomatosis) 01/2022 - 04/2005
8	Mesothelioma 12/2021 - 02/2002
7	Hypertension (High Blood Pressure) 01/2022 - 04/2011
6	Fatigue 10/2019 - 08/2008
5	Melanoma (Melanoma, Malignant) 07/2022 - 01/2014
5	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 04/2015
5	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2002
5	Diarrhea 01/2021 - 07/2008
4	Carcinogenesis 01/2022 - 03/2010
4	Infections 01/2021 - 01/2009
4	Chronic Renal Insufficiency 08/2019 - 01/2016
4	Brain Neoplasms (Brain Tumor) 01/2019 - 05/2008
4	Acute Kidney Injury (Acute Renal Failure) 01/2018 - 06/2012
3	COVID-19 01/2022 - 01/2020
3	Liver Neoplasms (Liver Cancer) 09/2021 - 07/2007
3	Fibrosis (Cirrhosis) 11/2020 - 01/2013
3	Stomatitis 05/2020 - 08/2008
3	Neutropenia 01/2018 - 01/2013
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2016 - 09/2012
2	Body Weight (Weight, Body) 05/2022 - 04/2018
2	Thrombosis (Thrombus) 01/2022 - 12/2004
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 08/2013
2	Circulating Neoplastic Cells 08/2021 - 01/2020
2	Kidney Diseases (Kidney Disease) 12/2020 - 01/2016
2	Hematologic Neoplasms (Hematological Malignancy) 12/2020 - 01/2018
2	Mucositis 05/2020 - 03/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2019 - 10/2011

Drug/Important Bio-Agent (IBA)

51	Sunitinib (Sutent)FDA Link 07/2022 - 08/2008
32	Sorafenib (BAY 43-9006)FDA Link 09/2021 - 07/2008
25	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2021 - 02/2002
24	NivolumabIBA 07/2022 - 04/2018
19	Tyrosine Kinase InhibitorsIBA 01/2022 - 05/2008
16	Immune Checkpoint InhibitorsIBA 04/2022 - 01/2018
16	pazopanib FDA Link 01/2022 - 01/2011
16	Everolimus FDA Link 01/2022 - 08/2008
13	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2014
10	IpilimumabIBA 01/2022 - 04/2018
9	Pharmaceutical PreparationsIBA 01/2022 - 01/2008
9	Bevacizumab (Avastin)FDA Link 01/2021 - 05/2009
8	cabozantinibIBA 07/2022 - 07/2019
8	Biological ProductsIBA 07/2021 - 01/2015
7	Angiogenesis InhibitorsIBA 12/2021 - 08/2013
7	Antineoplastic Agents (Antineoplastics)IBA 12/2020 - 09/2002
7	ARQ 197IBA 01/2018 - 01/2013
7	Interleukin-2 (IL2)IBA 11/2014 - 11/2002
6	MTOR InhibitorsIBA 01/2021 - 01/2014
6	LigandsIBA 11/2020 - 03/2011
6	TOR Serine-Threonine KinasesIBA 05/2020 - 08/2008
6	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020 - 05/2008
6	CytokinesIBA 02/2017 - 02/2003
5	pembrolizumabIBA 01/2022 - 03/2019
5	InterferonsIBA 11/2014 - 01/2006
5	Gemcitabine FDA Link 03/2011 - 05/2004
4	Cisplatin (Platino)FDA LinkGeneric 05/2022 - 05/2006
4	B7-H1 AntigenIBA 01/2022 - 01/2018
4	Monoclonal AntibodiesIBA 03/2021 - 04/2011
4	MMEIBA 01/2021 - 11/2002
4	tivozanibIBA 01/2021 - 11/2018
4	Proteins (Proteins, Gene)FDA Link 12/2020 - 01/2016
4	Phosphotransferases (Kinase)IBA 08/2019 - 01/2008
4	temsirolimus FDA Link 02/2016 - 05/2009
3	lenvatinibIBA 01/2022 - 03/2019
3	Axitinib (AG 013736)IBA 10/2020 - 01/2018
3	Hemoglobins (Hemoglobin)IBA 12/2019 - 04/2005
3	Interferon-alpha (Interferon Alfa)IBA 04/2010 - 10/2004
3	Carboplatin (JM8)FDA LinkGeneric 09/2009 - 09/2002
3	Imatinib Mesylate (Gleevec)FDA Link 01/2008 - 01/2007
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 09/2021 - 11/2016
2	DNA (Deoxyribonucleic Acid)IBA 08/2021 - 01/2016
2	Messenger RNA (mRNA)IBA 06/2021 - 04/2011
2	Lipase (Acid Lipase)FDA Link 01/2021 - 10/2019
2	PlatinumIBA 01/2021 - 09/2002
2	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2021 - 08/2015
2	Docetaxel (Taxotere)FDA Link 01/2021 - 04/2004
2	atezolizumabIBA 01/2021 - 01/2019
2	LipidsIBA 12/2020 - 09/2020
2	micaIBA 11/2020 - 01/2014
2	Nucleic AcidsIBA 09/2020 - 08/2019
2	Growth Factor ReceptorsIBA 01/2020 - 06/2005
2	Laminin (Merosin)IBA 11/2019 - 02/2019
2	Culture MediaIBA 02/2019 - 04/2018
2	Hormones (Hormone)IBA 04/2018 - 06/2016

Therapy/Procedure

88	Therapeutics 01/2022 - 09/2002
23	Immunotherapy 07/2022 - 05/2004
14	Drug Therapy (Chemotherapy) 03/2022 - 09/2002
10	Nephrectomy 01/2022 - 05/2006
4	Radiotherapy 01/2022 - 04/2004
4	Kidney Transplantation 12/2020 - 01/2016
3	Castration 01/2021 - 01/2016
2	Investigational Therapies (Experimental Therapy) 07/2022 - 04/2017
2	Renal Dialysis (Hemodialysis) 08/2019 - 07/2009
2	Renal Replacement Therapy (Therapies, Renal Replacement) 02/2019 - 01/2016
2	Molecular Targeted Therapy 01/2019 - 06/2005